GSK Expands AREXVY RSV Vaccine Indication to Higher-Risk Adults Aged 18–49
Event summary
- GSK’s AREXVY RSV vaccine approved in US for adults aged 18–49 with increased risk of severe disease, expanding from prior approvals for older age groups.
- FDA decision supported by Phase IIIb trial (NCT06389487) showing non-inferior immune response compared to adults 60+.
- Annual RSV burden in this age group includes ~17,000 hospitalizations and 277,000 emergency department visits in US.
- Vaccine uses GSK’s proprietary AS01E adjuvant system licensed from Antigenics LLC (Agenus subsidiary).
- AREXVY already approved in 70+ countries for adults 60+, with additional approvals for ages 50–59 at risk.
The big picture
This approval represents GSK’s strategic push to broaden RSV prevention beyond elderly populations, addressing a substantial medical need among younger adults with chronic conditions. The move aligns with industry trends toward preventative solutions for respiratory viruses and positions AREXVY as a potential standard in RSV prophylaxis across multiple age groups. With RSV-related hospitalizations costing the US healthcare system significantly, this expansion could both improve patient outcomes and create meaningful revenue streams.
What we're watching
- Market Expansion Pace
- Whether GSK can sustain regulatory approval momentum across additional geographies following this US expansion.
- Competitive Dynamics
- How this move positions AREXVY against potential RSV vaccine competitors targeting younger adult populations.
- Revenue Impact
- The contribution this expanded indication will make to GSK’s Vaccines division growth, particularly given the significant unmet need in high-risk younger adults.